BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $425 | +20.7% | 60,000 | +20.0% | 0.04% | +26.7% |
| Q2 2023 | $352 | -15.6% | 50,000 | 0.0% | 0.03% | -21.1% |
| Q1 2023 | $417 | -27.4% | 50,000 | 0.0% | 0.04% | -30.9% |
| Q4 2022 | $574 | -99.9% | 50,000 | 0.0% | 0.06% | -14.1% |
| Q3 2022 | $630,000 | +19.1% | 50,000 | 0.0% | 0.06% | +28.0% |
| Q2 2022 | $529,000 | -34.9% | 50,000 | 0.0% | 0.05% | -24.2% |
| Q1 2022 | $813,000 | +17.3% | 50,000 | 0.0% | 0.07% | +26.9% |
| Q4 2021 | $693,000 | -3.6% | 50,000 | 0.0% | 0.05% | -14.8% |
| Q3 2021 | $719,000 | -9.1% | 50,000 | 0.0% | 0.06% | -9.0% |
| Q2 2021 | $791,000 | +32.7% | 50,000 | -37.5% | 0.07% | +15.5% |
| Q4 2020 | $596,000 | +131.0% | 80,000 | +6.7% | 0.06% | +107.1% |
| Q3 2020 | $258,000 | -27.7% | 75,000 | 0.0% | 0.03% | -33.3% |
| Q2 2020 | $357,000 | +138.0% | 75,000 | 0.0% | 0.04% | +90.9% |
| Q1 2020 | $150,000 | -13.3% | 75,000 | +50.0% | 0.02% | +10.0% |
| Q4 2019 | $173,000 | -5.5% | 50,000 | -21.9% | 0.02% | -13.0% |
| Q3 2019 | $183,000 | +245.3% | 64,000 | +357.1% | 0.02% | +228.6% |
| Q2 2019 | $53,000 | -89.8% | 14,000 | -78.1% | 0.01% | -90.4% |
| Q1 2019 | $521,000 | +46.8% | 64,000 | +45.5% | 0.07% | +30.4% |
| Q4 2018 | $355,000 | +8.2% | 44,000 | +2.3% | 0.06% | +27.3% |
| Q3 2018 | $328,000 | +33.3% | 43,000 | 0.0% | 0.04% | +22.2% |
| Q2 2018 | $246,000 | +5.1% | 43,000 | -12.2% | 0.04% | +2.9% |
| Q1 2018 | $234,000 | -2.9% | 49,000 | 0.0% | 0.04% | -2.8% |
| Q4 2017 | $241,000 | -6.2% | 49,000 | 0.0% | 0.04% | -14.3% |
| Q3 2017 | $257,000 | -5.5% | 49,000 | 0.0% | 0.04% | -10.6% |
| Q2 2017 | $272,000 | -34.0% | 49,000 | 0.0% | 0.05% | -35.6% |
| Q1 2017 | $412,000 | +32.9% | 49,000 | 0.0% | 0.07% | +32.7% |
| Q4 2016 | $310,000 | +43.5% | 49,000 | 0.0% | 0.06% | +41.0% |
| Q3 2016 | $216,000 | +10.2% | 49,000 | -29.0% | 0.04% | +5.4% |
| Q2 2016 | $196,000 | +0.5% | 69,000 | 0.0% | 0.04% | -5.1% |
| Q1 2016 | $195,000 | -72.6% | 69,000 | 0.0% | 0.04% | -72.1% |
| Q4 2015 | $712,000 | -9.5% | 69,000 | 0.0% | 0.14% | -10.3% |
| Q3 2015 | $787,000 | -23.6% | 69,000 | 0.0% | 0.16% | -15.2% |
| Q2 2015 | $1,030,000 | +65.3% | 69,000 | 0.0% | 0.18% | +61.4% |
| Q1 2015 | $623,000 | -48.3% | 69,000 | -30.3% | 0.11% | -50.2% |
| Q4 2014 | $1,204,000 | +32.3% | 99,000 | +6.5% | 0.23% | +32.4% |
| Q3 2014 | $910,000 | -23.3% | 93,000 | 0.0% | 0.17% | -23.8% |
| Q2 2014 | $1,186,000 | +20.5% | 93,000 | 0.0% | 0.23% | +15.2% |
| Q1 2014 | $984,000 | -6.8% | 93,000 | -33.1% | 0.20% | -7.5% |
| Q4 2013 | $1,056,000 | +4.3% | 139,000 | 0.0% | 0.21% | -6.2% |
| Q3 2013 | $1,012,000 | +368.5% | 139,000 | 0.0% | 0.23% | +328.3% |
| Q2 2013 | $216,000 | – | 139,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |